Advertisement

Molecular Neurobiology

, Volume 54, Issue 7, pp 5008–5016 | Cite as

The Ubiquitin Ligase COP1 Promotes Glioma Cell Proliferation by Preferentially Downregulating Tumor Suppressor p53

  • Shenshan Zou
  • Yufu Zhu
  • Bin Wang
  • Fengyuan Qian
  • Xiang Zhang
  • Lei Wang
  • Chunling Fu
  • Hanmo Bao
  • Manyi Xie
  • Shangfeng Gao
  • Rutong YuEmail author
  • Hengliang ShiEmail author
Article

Abstract

Human glioma causes substantial morbidity and mortality worldwide. However, the molecular mechanisms underlying glioma progression are still largely unknown. COP1 (constitutively photomorphogenic 1), an E3 ubiquitin ligase, is important in cell survival, development, cell growth, and cancer biology by regulating different substrates. As is well known, both tumor suppressor p53 and oncogenic protein c-JUN could be ubiquitinated and degraded by ubiquitin ligase COP1, which may be the reason that COP1 serves as an oncogene or a tumor suppressor in different cancer types. Up to now, the possible role of COP1 in human glioma is still unclear. In the present study, we found that the expression of COP1 was upregulated in human glioma tissues. The role of COP1 in glioma cell proliferation was investigated using COP1 loss- and gain-of-function. The results showed that downregulation of COP1 by short hairpin RNA (shRNA) inhibited glioma cell proliferation, while overexpression of COP1 significantly promoted it. Furthermore, we demonstrated that COP1 only interacted with and regulated p53, but not c-JUN. Taken together, these results indicate that COP1 may play a role in promoting glioma cell proliferation by interacting with and downregulating tumor suppressor p53 rather than oncogenic protein c-JUN.

Keywords

Ubiquitin ligase COP1 p53 C-JUN Glioma 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81472345 and 81400127), the Natural Science Foundation of Jiangsu Province of China (BK20151165), the China Postdoctoral Science Foundation (2014M551662 and 2016T90507), and the Jiangsu Planned Projects for Postdoctoral Research Funds (1302111B and 1402191C).

Compliance with Ethical Standards

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21(21):2683–2710. doi: 10.1101/gad.1596707 CrossRefPubMedGoogle Scholar
  2. 2.
    Mrugala MM, Kesari S, Ramakrishna N, Wen PY (2004) Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther 4(5):759–782. doi: 10.1586/14737140.4.5.759 CrossRefPubMedGoogle Scholar
  3. 3.
    Norden AD, Wen PY (2006) Glioma therapy in adults. Neurologist 12(6):279–292. doi: 10.1097/01.nrl.0000250928.26044.47 CrossRefPubMedGoogle Scholar
  4. 4.
    Meyer MA (2008) Malignant gliomas in adults. N Engl J Med 359(17):1850 . doi: 10.1056/NEJMc086380author reply 1850PubMedGoogle Scholar
  5. 5.
    Deng XW, Caspar T, Quail PH (1991) cop1: a regulatory locus involved in light-controlled development and gene expression in Arabidopsis. Genes Dev 5(7):1172–1182. doi: 10.1101/gad.5.7.1172 CrossRefPubMedGoogle Scholar
  6. 6.
    Li YF, Wang DD, Zhao BW, Wang W, Huang CY, Chen YM, Zheng Y, Keshari RP, Xia JC, Zhou ZW (2012) High level of COP1 expression is associated with poor prognosis in primary gastric cancer. Int J Biol Sci 8(8):1168–1177. doi: 10.7150/ijbs.4778 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Marine JC (2012) Spotlight on the role of COP1 in tumorigenesis. Nat Rev Cancer 12(7):455–464. doi: 10.1038/nrc3271 CrossRefPubMedGoogle Scholar
  8. 8.
    Choi HH, Phan L, Chou PC, Su CH, Yeung SC, Chen JS, Lee MH (2015) COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth. Oncotarget 6(23):19721–19734CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bianchi E, Denti S, Catena R, Rossetti G, Polo S, Gasparian S, Putignano S, Rogge L, Pardi R (2003) Characterization of human constitutive photomorphogenesis protein 1, a RING finger ubiquitin ligase that interacts with Jun transcription factors and modulates their transcriptional activity. J Biol Chem 278(22):19682–19690. doi: 10.1074/jbc.M212681200 CrossRefPubMedGoogle Scholar
  10. 10.
    Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O’Rourke K, Koeppen H, Dixit VM (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429(6987):86–92. doi: 10.1038/Nature02514 CrossRefPubMedGoogle Scholar
  11. 11.
    Wang L, He G, Zhang P, Wang X, Jiang M, Yu L (2011) Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53. Mol Biol Rep 38(1):229–236. doi: 10.1007/s11033-010-0099-x CrossRefPubMedGoogle Scholar
  12. 12.
    Wertz IE, O’Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ, Dixit VM (2004) Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science 303(5662):1371–1374. doi: 10.1126/science.1093549 CrossRefPubMedGoogle Scholar
  13. 13.
    Shao J, Teng Y, Padia R, Hong S, Noh H, Xie X, Mumm JS, Dong Z, Ding HF, Cowell J, Kim J, Han J, Huang S (2013) COP1 and GSK3beta cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis. Neoplasia 15(9):1075–1085CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Vitari AC, Leong KG, Newton K, Yee C, O’Rourke K, Liu J, Phu L, Vij R, Ferrando R, Couto SS, Mohan S, Pandita A, Hongo JA, Arnott D, Wertz IE, Gao WQ, French DM, Dixit VM (2011) COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 474(7351):403–406. doi: 10.1038/nature10005 CrossRefPubMedGoogle Scholar
  15. 15.
    Ouyang M, Wang H, Ma J, Lu W, Li J, Yao C, Chang G, Bi J, Wang S, Wang W (2015) COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer. BMC Cancer 15:132. doi: 10.1186/s12885-015-1151-y CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lu G, Zhang Q, Huang Y, Song J, Tomaino R, Ehrenberger T, Lim E, Liu W, Bronson RT, Bowden M, Brock J, Krop IE, Dillon DA, Gygi SP, Mills GB, Richardson AL, Signoretti S, Yaffe MB, Kaelin WG Jr (2014) Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell 26(2):222–234. doi: 10.1016/j.ccr.2014.06.026 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Li DQ, Ohshiro K, Reddy SD, Pakala SB, Lee MH, Zhang Y, Rayala SK, Kumar R (2009) E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proc Natl Acad Sci U S A 106(41):17493–17498. doi: 10.1073/pnas.0908027106 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kato S, Ding J, Pisck E, Jhala US, Du K (2008) COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. J Biol Chem 283(51):35464–35473. doi: 10.1074/jbc.M801011200 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wei W, Kaelin WG Jr (2011) Good COP1 or bad COP1? In vivo veritas. J Clin Invest 121(4):1263–1265. doi: 10.1172/JCI57080 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, Koeppen H, Dixit VM, French DM (2004) COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res 64(20):7226–7230. doi: 10.1158/0008-5472.Can-04-2601 CrossRefPubMedGoogle Scholar
  21. 21.
    Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, Marquardt JU, Kitade M, Durkin ME, Raggi C, Woo HG, Conner EA, Avital I, Maclachlan I, Factor VM, Thorgeirsson SS (2010) Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res 70(21):8264–8269. doi: 10.1158/0008-5472.CAN-10-0749 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Su CH, Zhao R, Zhang F, Qu C, Chen B, Feng YH, Phan L, Chen J, Wang H, Wang H, Yeung SC, Lee MH (2011) 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability. Cancer Res 71(3):884–894. doi: 10.1158/0008-5472.CAN-10-2518 CrossRefPubMedGoogle Scholar
  23. 23.
    Migliorini D, Bogaerts S, Defever D, Vyas R, Denecker G, Radaelli E, Zwolinska A, Depaepe V, Hochepied T, Skarnes WC, Marine JC (2011) Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J Clin Invest 121(4):1329–1343. doi: 10.1172/JCI45784 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Shi H, Gao Y, Tang Y, Wu Y, Gong H, Du J, Zheng B, Hu J, Shi Q, Yu R (2014) CacyBP/SIP protein is important for the proliferation of human glioma cells. IUBMB Life 66(4):286–291. doi: 10.1002/iub.1263 CrossRefPubMedGoogle Scholar
  25. 25.
    Shi H, Zheng B, Wu Y, Tang Y, Wang L, Gao Y, Gong H, Du J, Yu R (2015) Ubiquitin ligase Siah1 promotes the migration and invasion of human glioma cells by regulating HIF-1alpha signaling under hypoxia. Oncol Rep 33(3):1185–1190. doi: 10.3892/or.2014.3695 PubMedGoogle Scholar
  26. 26.
    Wu Y, Wang L, Bao H, Zou S, Fu C, Gong H, Gao Y, Tang Y, Yu R, Shi H (2015) Nrdp1S, short variant of Nrdp1, inhibits human glioma progression by increasing Nrdp1-mediated ErbB3 ubiquitination and degradation. J Cell Mol Med. doi: 10.1111/jcmm.12735 Google Scholar
  27. 27.
    Savio MG, Rotondo G, Maglie S, Rossetti G, Bender JR, Pardi R (2008) COP1D, an alternatively spliced constitutive photomorphogenic-1 (COP1) product, stabilizes UV stress-induced c-Jun through inhibition of full-length COP1. Oncogene 27(17):2401–2411. doi: 10.1038/sj.onc.1210892 CrossRefPubMedGoogle Scholar
  28. 28.
    Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, Yates J 3rd, Montminy M (2007) Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449(7160):366–369. doi: 10.1038/nature06128 CrossRefPubMedGoogle Scholar
  29. 29.
    Qi L, Heredia JE, Altarejos JY, Screaton R, Goebel N, Niessen S, Macleod IX, Liew CW, Kulkarni RN, Bain J, Newgard C, Nelson M, Evans RM, Yates J, Montminy M (2006) TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. Science 312(5781):1763–1766. doi: 10.1126/science.1123374 CrossRefPubMedGoogle Scholar
  30. 30.
    Yoneda-Kato N, Tomoda K, Umehara M, Arata Y, Kato JY (2005) Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3. EMBO J 24(9):1739–1749. doi: 10.1038/sj.emboj.7600656 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Dornan D, Shimizu H, Mah A, Dudhela T, Eby M, O’Rourke K, Seshagiri S, Dixit VM (2006) ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science 313(5790):1122–1126. doi: 10.1126/science.1127335 CrossRefPubMedGoogle Scholar
  32. 32.
    Jin S, Levine AJ (2001) The p53 functional circuit. J Cell Sci 114(Pt 23):4139–4140PubMedGoogle Scholar
  33. 33.
    Ozaki T, Nakagawara A (2011) Role of p53 in cell death and human cancers. Cancers (Basel) 3(1):994–1013. doi: 10.3390/cancers3010994 CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49–53CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Shenshan Zou
    • 1
    • 2
  • Yufu Zhu
    • 1
    • 3
  • Bin Wang
    • 1
    • 2
  • Fengyuan Qian
    • 1
    • 2
  • Xiang Zhang
    • 1
    • 2
  • Lei Wang
    • 1
    • 3
  • Chunling Fu
    • 4
  • Hanmo Bao
    • 1
    • 2
  • Manyi Xie
    • 1
    • 3
  • Shangfeng Gao
    • 1
    • 3
  • Rutong Yu
    • 1
    • 3
    Email author
  • Hengliang Shi
    • 1
    • 3
    Email author
  1. 1.Insititute of Nervous System DiseasesXuzhou Medical CollegeXuzhouPeople’s Republic of China
  2. 2.The Graduate SchoolXuzhou Medical CollegeXuzhouChina
  3. 3.Brain HospitalAffiliated Hospital of Xuzhou Medical CollegeXuzhouPeople’s Republic of China
  4. 4.Institute of Blood DiseasesXuzhou Medical CollegeXuzhouChina

Personalised recommendations